Liraglutide 3.0 mg evaluated for long-term weight loss maintenance in obese subjects
Background
Achieving significant weight loss is challenging, but maintaining it long-term is often more difficult, with many individuals experiencing weight regain after initial success. Current standard-of-care often struggles to provide sustained efficacy for obesity management beyond initial dietary interventions. GLP-1 receptor agonists like liraglutide enhance satiety, reduce appetite, and improve glycemic control, making them promising candidates not just for initial weight reduction but also for preventing regain. This trial specifically addresses the critical need for effective pharmacological strategies to support weight loss maintenance after a low-calorie diet.
Study Design
This was a 56-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 trial (NCT00781937) with a 12-week follow-up. A total of 422 obese subjects underwent a 4 to 12-week low-calorie diet run-in period. Subjects who lost ≥5% of their screening body weight were randomized to receive either liraglutide 3.0 mg once daily, injected subcutaneously (SC), or a matching placebo. The intervention utilized a 6.0 mg/mL, 3 mL FlexPen®. Participants were instructed to follow a diet and exercise regimen throughout the study. The primary endpoint focused on long-term weight maintenance and additional weight loss.
Why It Matters
Effective strategies for weight loss maintenance are crucial, as regain is a major challenge in obesity management. This trial's design, focusing on subjects who already achieved initial weight loss through diet, directly addresses this clinical gap. If positive results were found, it would underscore the utility of liraglutide 3.0 mg as a sustained pharmacological aid, potentially extending its role beyond initial weight reduction to long-term management. For peptide users and clinicians, understanding how GLP-1 agonists perform in a maintenance setting could inform more durable treatment protocols, helping individuals sustain their health improvements and mitigate the frustration of weight cycling. This type of research is vital for developing comprehensive, long-term obesity care plans.
liraglutide
obesity
weight loss maintenance
phase 3
clinical trial
randomized controlled trial